<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of metabolic alkalosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of metabolic alkalosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of metabolic alkalosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ankit Mehta, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Emmett, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard H Sterns, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John P Forman, MD, MSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 28, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H9857747">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Metabolic alkalosis is characterized by a primary rise in the plasma bicarbonate concentration, which leads to an increase in arterial pH. Two factors are required for the genesis and then maintenance of metabolic alkalosis: a process that raises the plasma bicarbonate concentration and a process that prevents excretion of the excess bicarbonate in the urine [
         <a href="#rid1">
          1,2
         </a>
         ]. Treatment of metabolic alkalosis should be aimed at reversing these two factors.
        </p>
        <p>
         This topic will provide a brief overview of the pathogenesis of metabolic alkalosis followed by a discussion of how to treat affected patients. The pathogenesis of metabolic alkalosis is reviewed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2330.html" rel="external">
          "Pathogenesis of metabolic alkalosis"
         </a>
         .)
        </p>
        <p>
         The etiology and evaluation of patients with metabolic alkalosis are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2331.html" rel="external">
          "Causes of metabolic alkalosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2312.html" rel="external">
          "Clinical manifestations and evaluation of metabolic alkalosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1039092">
         <span class="h1">
          OVERVIEW OF THE PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The genesis and the maintenance of metabolic alkalosis are distinct processes. Initially, a process that raises the plasma bicarbonate concentration occurs, and then another process prevents excretion of the excess bicarbonate in the urine [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9319111">
         <span class="h2">
          Factors that increase plasma bicarbonate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several mechanisms can increase the plasma bicarbonate concentration. They include (
         <a class="graphic graphic_table graphicRef57489" href="/z/d/graphic/57489.html" rel="external">
          table 1
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/2331.html" rel="external">
          "Causes of metabolic alkalosis"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hydrogen loss from the body due to removal of gastric secretions (as with vomiting or tube drainage), loss in the stool when gastrointestinal bicarbonate and chloride transport is abnormal (chloride wasting diarrhea), or excessive urinary acid secretion (due, for example, to loop or thiazide diuretics or primary mineralocorticoid excess).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Shift of hydrogen ions from the extracellular fluid (ECF) into the cells. This is most often due to hypokalemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exogenous administration of
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         or other sodium salts that are metabolized to form sodium bicarbonate.
        </p>
        <p>
        </p>
        <p>
         A less common cause is contraction alkalosis due to the loss of relatively large volumes of bicarbonate-free fluid. This, in part, contributes to the rise in serum bicarbonate when loop diuretics are used to treat patients with marked edema.
        </p>
        <p class="headingAnchor" id="H9319118">
         <span class="h2">
          Factors that impair bicarbonate excretion
         </span>
         <span class="headingEndMark">
          —
         </span>
         The normal kidney filters more than 4000 mEq of bicarbonate per day. This number increases if the serum HCO3 concentration is elevated. Thus, a high serum bicarbonate concentration could be readily corrected by excretion of the excess bicarbonate into the urine. However, such correction will not occur if kidney filtration is markedly reduced or the renal tubules avidly reabsorb the filtered bicarbonate. The importance of reduced bicarbonate excretion for maintenance of metabolic alkalosis was illustrated in a study of adults who had a gastric or duodenal ulcer and were treated with
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         at a dose ranging from 8 to 24 mEq/kg per day (approximately 500 to 1500 mEq per day) for two to three weeks. These large doses of sodium bicarbonate produced only small elevations in the plasma bicarbonate concentration of approximately 3 to 4 mEq/L because nearly all of the ingested bicarbonate was excreted in the urine [
         <a href="#rid3">
          3
         </a>
         ]. A major rise in serum bicarbonate requires a major reduction in renal bicarbonate excretion.
        </p>
        <p>
         The most common cause of impaired bicarbonate excretion in patients with metabolic alkalosis is a reduction in arterial blood volume or in the effective arterial blood volume (EABV). EABV is a difficult-to-measure entity that refers to the arterial volume that perfuses the tissues [
         <a href="#rid1">
          1
         </a>
         ]. A reduction in EABV stimulates the kidney to retain sodium salts and, because bicarbonate must be excreted with sodium or potassium to maintain electroneutrality, this sodium avidity limits the excretion of bicarbonate. In addition, reduced EABV increases chloride reabsorption proximally and severely reduces the distal delivery of chloride; this limits bicarbonate secretion (in exchange for luminal chloride) by type B intercalated cells in the distal tubule and collecting ducts [
         <a href="#rid4">
          4
         </a>
         ]. The net effect is that renal bicarbonate excretion is largely eliminated by the presence of a reduced EABV. Under these circumstances, patients may excrete a "paradoxically" acid urine (paradoxical aciduria) despite the presence of metabolic alkalosis [
         <a href="#rid2">
          2,5
         </a>
         ].
        </p>
        <p>
         The most common causes of a true volume depletion associated with metabolic alkalosis are vomiting or diuretic therapy. The most common causes of reduced EABV are heart failure and cirrhosis.
        </p>
        <p>
         Hypokalemia can also reduce renal bicarbonate excretion, in part because it stimulates renal ammoniagenesis and ammonium excretion (ammonium excreted with chloride represents renal tubule bicarbonate generation, while ammonium excreted with bicarbonate has no net acid-base impact).
        </p>
        <p>
         In addition, acute and chronic kidney disease reduces the capacity to excrete bicarbonate. Thus, bicarbonate administration or generation in such patients can generate a persistent metabolic alkalosis. However, metabolic acidosis is much more common in patients with reduced kidney function as a result of an inability to excrete the daily dietary acid load generated by typical Western meat-containing diets.
        </p>
        <p>
         Virtually all clinical situations associated with true arterial volume contraction, or a reduced EABV, generate avid renal chloride reabsorption. Reduced chloride delivery to the distal tubules markedly impairs the kidney's capacity to excrete bicarbonate and thereby impairs the kidney's capacity to prevent the development, or correct the presence, of metabolic alkalosis. The mechanisms by which these changes occur are discussed elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2330.html" rel="external">
          "Pathogenesis of metabolic alkalosis", section on 'Hypokalemia'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2330.html" rel="external">
          "Pathogenesis of metabolic alkalosis", section on 'Chloride depletion'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2293.html" rel="external">
          "Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9857754">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of metabolic alkalosis should be aimed at two targets:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The source of bicarbonate generation (or administration)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         and
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reversing the factors that prevent the kidneys from excreting the excess bicarbonate
        </p>
        <p>
        </p>
        <p>
         In order to accomplish this, two questions must be answered:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Is the increase in plasma bicarbonate concentration due to gastrointestinal or renal hydrogen ion loss (eg, vomiting, diuretic therapy), contraction of the extracellular fluid (ECF) volume, an intracellular shift of hydrogen ions, an exogenous load of alkali or alkali precursors, or a combination of these factors (
         <a class="graphic graphic_table graphicRef57489" href="/z/d/graphic/57489.html" rel="external">
          table 1
         </a>
         )?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Why is the excess bicarbonate not being excreted in the urine? As discussed above, the major causes of reduced renal bicarbonate excretion are reduced arterial blood volume or effective arterial blood volume (EABV; associated with chloride depletion or inadequate distal tubule chloride delivery), hypokalemia, and acute or chronic kidney disease. (See
         <a class="local">
          'Factors that impair bicarbonate excretion'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1863594">
         <span class="h2">
          Treat the underlying cause
         </span>
         <span class="headingEndMark">
          —
         </span>
         The underlying etiology of the alkalosis should be addressed (eg, treat the cause of vomiting, stop or reduce the removal of gastric secretions, reduce the acid content of the gastrointestinal secretions, and, if possible, stop loop or thiazide diuretics). (See
         <a class="medical medical_review" href="/z/d/html/2331.html" rel="external">
          "Causes of metabolic alkalosis", section on 'Gastrointestinal hydrogen loss'
         </a>
         .)
        </p>
        <p>
         Patients who develop metabolic alkalosis as a result of persistent vomiting or gastric suction can be effectively treated with drugs that reduce gastric hydrochloric acid (HCl) secretion. Both H2 blockers and proton pump inhibitors have been utilized [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p>
         All exogenous sources of alkali should be discontinued to the extent possible. This includes sodium or potassium bicarbonate and sodium or potassium salts of any organic anion that is metabolized and thereby generates bicarbonate, such as citrate or lactate. Bicarbonate administered to patients with reversible organic metabolic acidosis (usually lactic or ketoacidosis) can also be considered "excess" bicarbonate (to the extent that the organic anion has been retained in body fluids) and can result in a "rebound" or postcorrection metabolic alkalosis. This occurs because, after correction of the hypotension or insulin deficiency, metabolism of the lactate or beta-hydroxybutyrate regenerates bicarbonate. Thus, the exogenously administered
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         will then represent "excess" bicarbonate. (See
         <a class="medical medical_review" href="/z/d/html/2294.html" rel="external">
          "Bicarbonate therapy in lactic acidosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1795.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Treatment", section on 'Bicarbonate and metabolic acidosis'
         </a>
         .)
        </p>
        <p>
         Hypokalemia commonly occurs in these patients and, if present, should be reversed. (See
         <a class="medical medical_review" href="/z/d/html/2331.html" rel="external">
          "Causes of metabolic alkalosis", section on 'Hypokalemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1863671">
         <span class="h2">
          Increase renal bicarbonate excretion
         </span>
         <span class="headingEndMark">
          —
         </span>
         The maintenance of metabolic alkalosis requires a reduction in the renal excretion of the excess bicarbonate. Reversing the factors that impair renal bicarbonate excretion will correct the alkalosis. (See
         <a class="medical medical_review" href="/z/d/html/2330.html" rel="external">
          "Pathogenesis of metabolic alkalosis", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p>
         The most important factors that impair renal bicarbonate excretion include (see
         <a class="local">
          'Factors that impair bicarbonate excretion'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A reduced arterial blood volume or EABV
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chloride depletion, hypochloremia, and reduced distal tubule chloride delivery (almost always associated with reduced arterial or EABV)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Potassium depletion and hypokalemia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced kidney function
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1863706">
         <span class="h3">
          Reduced arterial or effective arterial blood volume and chloride depletion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Reduced arterial blood volume or EABV is almost invariably associated with chloride depletion, and a high serum bicarbonate concentration is almost invariably associated with hypochloremia. If the arterial volume depletion can be treated and reversed with isotonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         (sodium chloride), this will simultaneously restore arterial volume, correct the chloride deficit, and increase renal
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         excretion.
        </p>
        <p>
         All forms of reduced arterial blood volume and EABV promote persistence of metabolic alkalosis since the kidney is stimulated to retain sodium, and this limits the ability to excrete bicarbonate. Causes of true volume depletion include vomiting, nasogastric suction, diuretic therapy, marked sweat loss (especially with a high sweat salt concentration as in cystic fibrosis), blood loss, loss of fluid into the "third" space, and, rarely, villous adenoma (
         <a class="graphic graphic_table graphicRef57489" href="/z/d/graphic/57489.html" rel="external">
          table 1
         </a>
         ). Causes of EABV depletion include heart failure and cirrhosis. These causes of low EABV do not respond to
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         volume expansion, and such treatment can result in clinical deterioration. (See
         <a class="local">
          'Factors that impair bicarbonate excretion'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1864356">
         <span class="h4">
          True volume depletion
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with true arterial volume depletion, but not in heart failure and cirrhosis, the metabolic alkalosis should be corrected by expanding volume. Usually, this is accomplished with isotonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         , which expands the ECF and intravascular compartment. A reasonable regimen in patients with mild-to-moderate hypovolemia is to administer isotonic saline at a rate that is approximately 100 mL/hour greater than the sum of urine output plus other fluid losses that may be present (eg, gastrointestinal losses). More aggressive therapy is required in patients with severe hypovolemia. (See
         <a class="medical medical_review" href="/z/d/html/2296.html" rel="external">
          "Maintenance and replacement fluid therapy in adults", section on 'Rate of replacement'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1607.html" rel="external">
          "Treatment of severe hypovolemia or hypovolemic shock in adults", section on 'Initial rate of fluid repletion'
         </a>
         .)
        </p>
        <p>
         Appropriate repletion of the extracellular and intravascular volume has the following beneficial acid/base effects in patients with metabolic alkalosis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A reduction in proximal and distal
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         reabsorption, which will increase urinary bicarbonate excretion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A reduction in proximal chloride reabsorption, resulting in increased chloride delivery to the distal nephron.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The increase in distal tubule fluid volume and chloride delivery will reduce acid secretion and promote connecting segment and collecting tubule bicarbonate secretion via the chloride-bicarbonate anion exchanger (pendrin) located on the luminal surface of type B intercalated cells (
         <a class="graphic graphic_figure graphicRef62465" href="/z/d/graphic/62465.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid5">
          5,8-11
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The resulting increase in bicarbonate excretion should be reflected by an alkaline urine pH, which will exceed 7 when significant bicarbonaturia exists.
        </p>
        <p class="headingAnchor" id="H1864600">
         <span class="h4">
          Edematous states
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with edematous states such as heart failure, cirrhosis, nephrotic syndrome, and cor pulmonale can develop metabolic alkalosis. This is often due to diuretic therapy. Treatment with isotonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         is generally
         <strong>
          contraindicated
         </strong>
         in edematous patients for two reasons: It will increase edema, ascites, and/or effusions, and it will
         <strong>
          not
         </strong>
         correct the metabolic alkalosis since the underlying renal sodium avidity will persist, limiting urinary excretion of the excess bicarbonate. These patients may be hypokalemic and potassium depleted. In such patients, the metabolic alkalosis is often improved or even corrected by administering
         <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">
          potassium chloride
         </a>
         . The addition of potassium-sparing diuretics such as
         <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">
          amiloride
         </a>
         may also be helpful. (See
         <a class="local">
          'Potassium depletion'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/6884.html" rel="external">
          "General principles of the treatment of edema in adults", section on 'Use of diuretics'
         </a>
         .)
        </p>
        <p>
         With respect to potassium-sparing diuretics, patients with heart failure or cirrhosis are often treated with a mineralocorticoid receptor antagonist (
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         or
         <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">
          eplerenone
         </a>
         ). However, their use must be carefully monitored to avoid development of potentially life-threatening hyperkalemia. (See
         <a class="medical medical_review" href="/z/d/html/1256.html" rel="external">
          "Ascites in adults with cirrhosis: Initial therapy", section on 'Diuretic regimen'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1256.html" rel="external">
          "Ascites in adults with cirrhosis: Initial therapy", section on 'Diuretic therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">
          "Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Mineralocorticoid receptor antagonist'
         </a>
         .)
        </p>
        <p>
         If additional diuresis is required, the carbonic anhydrase inhibitor,
         <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">
          acetazolamide
         </a>
         , can be administered (250 to 500 mg, once or twice a day) [
         <a href="#rid1">
          1
         </a>
         ]. Acetazolamide is a carbonic anhydrase inhibitor that primarily inhibits proximal
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         reabsorption, thereby increasing urinary bicarbonate excretion. (See
         <a class="medical medical_review" href="/z/d/html/2338.html" rel="external">
          "Mechanism of action of diuretics", section on 'Carbonic anhydrase inhibitors (acetazolamide)'
         </a>
         .)
        </p>
        <p>
         In patients treated with
         <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">
          acetazolamide
         </a>
         , the increase in
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         delivery to the potassium-secretory site in the collecting tubules will generate kaliuresis and can cause or worsen hypokalemia.
         <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">
          Potassium chloride
         </a>
         replacement may be necessary. Contraindications to acetazolamide therapy include hypersensitivity to sulfonamides, severe liver disease, hypokalemia (as noted), some forms of chronic lung disease, and severe kidney disease [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1864673">
         <span class="h4">
          Chloride depletion
         </span>
         <span class="headingEndMark">
          —
         </span>
         As mentioned above, when sodium and potassium are administered, they should be given with chloride to correct metabolic alkalosis [
         <a href="#rid8">
          8,13
         </a>
         ]. Volume expansion with chloride salts reduces proximal tubule bicarbonate reabsorption and increases the distal tubule delivery of sodium and chloride where the chloride is reabsorbed in exchange for bicarbonate in the connecting segment and collecting tubules by a luminal chloride/bicarbonate exchanger called pendrin (
         <a class="graphic graphic_figure graphicRef62465" href="/z/d/graphic/62465.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         Whether resolution of hypovolemia or repletion of the chloride deficit is the key factor responsible for correcting metabolic alkalosis in response to
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         infusion is the subject of ongoing debate [
         <a href="#rid8">
          8
         </a>
         ]. Some experimental models support the principal role of chloride depletion. As an example, administration of chloride with a nonsodium cation (such as choline) can correct some experimental forms of metabolic alkalosis [
         <a href="#rid14">
          14
         </a>
         ] but administration of sodium with a nonchloride anion (such as sulfate or nitrate) does not [
         <a href="#rid2">
          2,15
         </a>
         ]. However, anions such as sulfate and nitrate are freely filtered and delivered to the distal renal tubules, where they cannot be readily reabsorbed. Under those conditions, reabsorption of sodium without an accompanying anion causes the anion to be excreted with ammonium (NH4), titratable acid (H2PO4), and/or potassium, preventing correction of the metabolic alkalosis and further depleting potassium stores [
         <a href="#rid1">
          1,16
         </a>
         ]. In addition, virtually all clinical forms of ECF volume contraction are associated with chloride depletion, and volume expansion requires sodium chloride salts.
        </p>
        <p class="headingAnchor" id="H9857783">
         <span class="h3">
          Potassium depletion
         </span>
         <span class="headingEndMark">
          —
         </span>
         The administration of
         <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">
          potassium chloride
         </a>
         is an important component of the treatment of most forms of metabolic alkalosis [
         <a href="#rid1">
          1,16
         </a>
         ].
        </p>
        <p>
         Potassium depletion with hypokalemia enhances proximal tubule bicarbonate reabsorption and also activates a collecting tubule H-K-ATPase that reabsorbs potassium in exchange for secreted hydrogen. This will increase bicarbonate reabsorption and bicarbonate generation, which act together to maintain the alkalosis [
         <a href="#rid17">
          17
         </a>
         ]. Correction of hypokalemia will decrease the activity of this cation exchanger, allowing bicarbonate to be excreted in the urine.
        </p>
        <p>
         In addition,
         <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">
          potassium chloride
         </a>
         replacement restores the large intracellular potassium deficit that accompanies hypokalemia in most forms of metabolic alkalosis. The movement of administered potassium into cells occurs, in part, in exchange for intracellular hydrogen ions to maintain electroneutrality [
         <a href="#rid16">
          16
         </a>
         ]. The movement of hydrogen ions out of cells and the repletion of intracellular potassium have several important effects, each of which will lower the plasma bicarbonate concentration:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The hydrogen ions entering the ECF reduce the extracellular bicarbonate concentration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Raising the renal tubular cell pH reduces hydrogen ion secretion (and therefore bicarbonate reabsorption) and also reduces renal ammonium excretion [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The use of potassium salts to correct hypokalemia is discussed in detail elsewhere. When potassium salts are administered to patients with metabolic alkalosis,
         <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">
          potassium chloride
         </a>
         <strong>
          is the preferred preparation
         </strong>
         . Potassium salts of organic anions, such as citrate or acetate, should be
         <strong>
          avoided
         </strong>
         , if possible, since metabolism of these anions generates bicarbonate, which will slow the rate of correction of the metabolic alkalosis. (See
         <a class="medical medical_review" href="/z/d/html/2297.html" rel="external">
          "Clinical manifestations and treatment of hypokalemia in adults", section on 'Potassium preparations'
         </a>
         .)
        </p>
        <p>
         The usual dose of potassium is 10 to 20 mEq given two to four times per day (20 to 80 mEq per day), depending upon the severity of the hypokalemia.
         <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">
          Potassium chloride
         </a>
         can be given intravenously in patients who are unable to take oral medications or as an adjunct to oral therapy in patients who have severe or symptomatic hypokalemia. These issues are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2297.html" rel="external">
          "Clinical manifestations and treatment of hypokalemia in adults", section on 'Mild to moderate hypokalemia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2297.html" rel="external">
          "Clinical manifestations and treatment of hypokalemia in adults", section on 'Severe or symptomatic hypokalemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9857818">
         <span class="h2">
          Treatment of posthypercapnic metabolic alkalosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic respiratory acidosis, which is most often due to chronic obstructive pulmonary disease, is initially associated with increased renal acid excretion and later with increased bicarbonate reabsorption. This results in a compensatory increase in the serum bicarbonate concentration that mitigates the fall in arterial pH (
         <a class="graphic graphic_figure graphicRef63315" href="/z/d/graphic/63315.html" rel="external">
          figure 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2352.html" rel="external">
          "Simple and mixed acid-base disorders", section on 'Response to respiratory acidosis'
         </a>
         .)
        </p>
        <p>
         If the partial pressure of carbon dioxide (PCO2) is reduced rapidly as a result of mechanical ventilation and/or medical intervention and the serum bicarbonate concentration remains elevated, this represents a posthypercapnic metabolic alkalosis (the PCO2 is reduced toward normal, but the bicarbonate concentration remains "inappropriately" elevated). Such patients often cannot spontaneously excrete the excess bicarbonate because of a combination of chloride depletion, a reduction in the EABV (due, for example, to diuretic therapy or cor pulmonale), and/or a reduction in glomerular filtration rate. Posthypercapnic metabolic alkalosis can worsen ventilation, exacerbate respiratory acidosis, retard weaning from artificial ventilation, and prolong the intensive care unit (ICU) stay [
         <a href="#rid19">
          19,20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2331.html" rel="external">
          "Causes of metabolic alkalosis", section on 'Posthypercapnic alkalosis'
         </a>
         .)
        </p>
        <p>
         When posthypercapnic metabolic alkalosis is due to volume depletion, it can usually be corrected with an isotonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         infusion [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2331.html" rel="external">
          "Causes of metabolic alkalosis", section on 'Posthypercapnic alkalosis'
         </a>
         and
         <a class="local">
          'Chloride depletion'
         </a>
         above.)
        </p>
        <p>
         However, if the patient requires additional diuresis, then posthypercapnic metabolic alkalosis can be treated with
         <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">
          acetazolamide
         </a>
         , a diuretic that increases urinary
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         (and potassium) excretion. Several reports suggested that acetazolamide improved the respiratory acidosis, as manifested by a fall in arterial PCO2 [
         <a href="#rid19">
          19-21
         </a>
         ]. By contrast, one randomized study found that acetazolamide failed to shorten the duration on artificial ventilation compared with placebo, despite a "biochemical" improvement in arterial PCO2 [
         <a href="#rid22">
          22
         </a>
         ]. However, the severity of treated metabolic alkalosis in this trial was mild, limiting the conclusions that can be drawn [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         Red blood cell carbonic anhydrase plays a role in the transport of CO2 from red blood cells to the alveolar space. Thus, inhibition of this enzyme with
         <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">
          acetazolamide
         </a>
         can cause a small and transient rise in the arterial PCO2 [
         <a href="#rid12">
          12,19,23
         </a>
         ]. This effect is not clinically significant in most patients.
        </p>
        <p>
         Other forms of metabolic alkalosis can also complicate chronic respiratory acidosis (gastric aspiration, glucocorticoid treatment, aggressive diuresis, etc), and correction of this superimposed derangement can improve respiratory status, as reflected in lower PCO2 levels and improved oxygen exchange in critically ill patients [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9857825">
         <span class="h2">
          Treatment of metabolic alkalosis with acute or chronic kidney disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Metabolic alkalosis can develop in patients with acute or chronic kidney disease in whom therapies aimed at increasing urinary bicarbonate excretion are less likely to be effective (unless their kidney dysfunction is largely due to reversible ECF volume depletion). In some cases, dialysis will be indicated. Dialysis with a low-bicarbonate bath concentration will rapidly improve the alkalosis. However, it may be difficult to markedly reduce bicarbonate bath concentrations. Because the patient's bicarbonate in such cases is much higher than a standard dialysis bicarbonate bath concentration, routine dialysis will improve the metabolic alkalosis, albeit less effectively than dialysis with a low-bicarbonate bath [
         <a href="#rid25">
          25,26
         </a>
         ].
        </p>
        <p>
         Continuous kidney replacement therapy (CKRT) can be used to correct metabolic alkalosis in patients requiring kidney replacement therapy. When high rates of ultrafiltration are used, the composition of the replacement fluid can markedly alter the electrolyte and acid-base status of the patient. If the replacement fluid contains relatively high concentrations of
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         , or precursors of sodium bicarbonate such as
         <a class="drug drug_general" data-topicid="10267" href="/z/d/drug information/10267.html" rel="external">
          sodium lactate
         </a>
         or sodium citrate (potential bicarbonate), then the bicarbonate concentration of the patient can increase. Conversely, adjusting the replacement fluid to reduce the concentration of sodium bicarbonate, and potential bicarbonate salts, can reduce the patient's bicarbonate concentration [
         <a href="#rid27">
          27,28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1845.html" rel="external">
          "Continuous kidney replacement therapy in acute kidney injury"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H432636008">
         <span class="h2">
          Hydrochloric acid in selected patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with severe metabolic alkalosis (for example, bicarbonate greater than 50 mEq/L and/or pH greater than 7.55) who have kidney function impairment and cannot, or should not, be dialyzed can be treated with an intravenous infusion of HCl or an HCl precursor such as ammonium chloride, which is metabolized to urea and HCl.
        </p>
        <p>
         HCl for infusion can be prepared by passing 100 mL of 1 normal (1 N) HCl through a 22 microm filter into 900 mL of isotonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         , or sterile water, to produce a 0.1 N (100 mEq/L) solution of HCl [
         <a href="#rid29">
          29
         </a>
         ]. This solution must then be infused through a carefully placed, free-flowing central venous catheter into the superior vena cava over 8 to 24 hours [
         <a href="#rid29">
          29-31
         </a>
         ]. Because HCl may react with plastic, use of glass containers is recommended, and intravenous tubing should be changed every 12 hours [
         <a href="#rid29">
          29
         </a>
         ]. Caution is required because infiltration of this solution will necrose tissues, and this complication can be fatal [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         In one report, HCl was mixed with an amino acid and fat emulsion solution, which raises the pH sufficiently so that it can safely be infused into a peripheral vein [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         Ammonium chloride (NH4Cl) is available in 20 mL vials that contain 100 mEq of NH4Cl. One or two vials are added to 1000 mL of isotonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         [
         <a href="#rid34">
          34,35
         </a>
         ]. However, the ammonium is metabolized to urea, and the urea concentration can increase sharply in patients with kidney function impairment. Also, high ammonia levels may develop, especially in patients with liver disease, and can produce central nervous system manifestations. (See
         <a class="medical medical_review" href="/z/d/html/1257.html" rel="external">
          "Hepatic encephalopathy: Pathogenesis", section on 'Ammonia'
         </a>
         .)
        </p>
        <p>
         Arginine hydrochloride, which is approved for use in the United States as a diagnostic infusion to test pituitary function, has been used to treat metabolic alkalosis. However, it is not approved in the United States for this indication, and we do not recommend that it be used to treat metabolic alkalosis, because it can cause potassium to shift from cells into the extracellular space, resulting in life-threatening hyperkalemia [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         A rough estimate of the amount of acid or acid precursor (in mEq) that will be required to reduce the plasma bicarbonate can be determined by multiplying the desired change in plasma bicarbonate concentration by the space of distribution of bicarbonate, which is roughly equal to the total body water (approximately 60 and 50 percent of lean body weight [LBW] in males and females, respectively).
        </p>
        <p>
         Thus, in males:
        </p>
        <div class="formulaContainer">
         <div class="formula">
          <p>
           HCO3 excess (in mEq)  =  0.6  x  LBW  x  (desired plasma HCO3 reduction)
          </p>
         </div>
        </div>
        <p>
         In females:
        </p>
        <div class="formulaContainer">
         <div class="formula">
          <p>
           HCO3 excess (in mEq)  =  0.5  x  LBW  x  (desired plasma HCO3 reduction)
          </p>
         </div>
        </div>
        <p>
         However, this formula is a very
         <strong>
          rough initial estimate
         </strong>
         . It does
         <strong>
          not
         </strong>
         take into account continuing acid losses (as with nasogastric suction), changes in volume status, changes in bicarbonate distribution space related to the bicarbonate concentration, potassium balance, or kidney function. If acid infusion is prescribed, the goal should be partial correction of the alkalosis with intermittent reassessment. Thus, in these rare instances in which acid therapy is used, we recommend that only one liter of solution (containing 100 mEq of HCl or NH4Cl) be infused. Then, serum chemistries should be remeasured, and the clinical status should be reassessed to determine whether or not additional acid therapy is required.
        </p>
        <p class="headingAnchor" id="H3016554255">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109733.html" rel="external">
          "Society guideline links: Fluid and electrolyte disorders in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1865513">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two factors are required for the genesis and then maintenance of metabolic alkalosis: a process that raises the plasma bicarbonate concentration (
         <a class="graphic graphic_table graphicRef57489" href="/z/d/graphic/57489.html" rel="external">
          table 1
         </a>
         ) and a process that prevents excretion of the excess bicarbonate in the urine. (See
         <a class="local">
          'Overview of the pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The most common causes of impaired renal bicarbonate excretion in patients with metabolic alkalosis are a reduction in the effective arterial blood volume (EABV; also called effective circulating volume), chloride depletion, hypokalemia, and acute and chronic kidney disease. (See
         <a class="local">
          'Factors that impair bicarbonate excretion'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of metabolic alkalosis should be aimed at reversing the etiology of bicarbonate generation and reversing the factors that prevent the excretion of the excess bicarbonate. In order to accomplish this, two questions must be answered (see
         <a class="local">
          'Treatment'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Is the increase in plasma bicarbonate concentration due to an exogenous alkali load, gastrointestinal or renal hydrogen ion loss (eg, vomiting, diuretic therapy) with or without contraction alkalosis, an intracellular shift of hydrogen ions, or a combination of these disorders (
         <a class="graphic graphic_table graphicRef57489" href="/z/d/graphic/57489.html" rel="external">
          table 1
         </a>
         )?
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Why is the excess bicarbonate not being excreted in the urine?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The underlying etiology of the alkalosis should be reversed (eg, treating the cause of vomiting, stopping or slowing the removal of gastric secretions and reducing the acidity of these secretions, and stopping loop or thiazide diuretics). Any exogenous sources of alkali should be discontinued. Hypokalemia, which is often present, should be corrected. (See
         <a class="local">
          'Treat the underlying cause'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maintenance of metabolic alkalosis is due to a reduction in the renal excretion of the excess bicarbonate. The reversal of metabolic alkalosis requires the renal excretion of bicarbonate whenever possible. (See
         <a class="local">
          'Increase renal bicarbonate excretion'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced EABV and chloride depletion usually occur together, and the treatment of EABV depletion with isotonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         (sodium chloride) simultaneously corrects the volume and chloride deficits. This generally increases renal bicarbonate excretion in patients with true volume depletion. However, isotonic saline is not indicated when the EABV depletion is caused by conditions such as heart failure or cirrhosis. (See
         <a class="local">
          'Reduced arterial or effective arterial blood volume and chloride depletion'
         </a>
         above and
         <a class="local">
          'True volume depletion'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When metabolic alkalosis develops in patients with reduced EABV due to conditions such as heart failure or cirrhosis, treatment includes the administration of
         <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">
          potassium chloride
         </a>
         and/or a potassium-sparing diuretic or, uncommonly,
         <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">
          acetazolamide
         </a>
         if further diuresis is required. (See
         <a class="local">
          'Edematous states'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypokalemia in patients with metabolic alkalosis represents a large intracellular potassium deficit. The administration of
         <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">
          potassium chloride
         </a>
         corrects both the potassium deficit and helps reverse the metabolic alkalosis. (See
         <a class="local">
          'Potassium depletion'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic respiratory acidosis, which is most often due to chronic obstructive pulmonary disease, is initially associated with increased renal acid excretion and, later, with increased bicarbonate reabsorption. This produces a compensatory increase in the serum bicarbonate concentration that mitigates the fall in arterial pH (
         <a class="graphic graphic_figure graphicRef63315" href="/z/d/graphic/63315.html" rel="external">
          figure 2
         </a>
         ). If the chronic respiratory acidosis improves as a result of mechanical ventilation and/or medical intervention, a posthypercapnic metabolic alkalosis may develop. Many patients with posthypercapnic metabolic alkalosis can be effectively treated with isotonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         infusion, which corrects EABV and chloride deficits. Another option for the treatment of posthypercapnic metabolic alkalosis is
         <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">
          acetazolamide
         </a>
         , which increases urinary bicarbonate excretion. (See
         <a class="local">
          'Treatment of posthypercapnic metabolic alkalosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Uncommonly, patients with metabolic alkalosis do not adequately respond to, or are not candidates for, conventional therapies (volume expansion, chloride repletion, and potassium repletion) or therapy with
         <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">
          acetazolamide
         </a>
         . One example is metabolic alkalosis developing in patients with advanced acute or chronic kidney disease. Such patients can often be treated with dialysis. (See
         <a class="local">
          'Treatment of metabolic alkalosis with acute or chronic kidney disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Continuous kidney replacement therapy (CKRT) can generate metabolic alkalosis (due to the infusion of
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         and potential bicarbonate such as lactate or citrate) but can also be utilized to correct metabolic alkalosis. (See
         <a class="local">
          'Treatment of metabolic alkalosis with acute or chronic kidney disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rarely, patients with severe metabolic alkalosis (eg, HCO3 greater than 50 mEq/L and/or pH greater than 7.55) fail or are not candidates for conventional therapies and cannot, or should not, be dialyzed. Such patients can be treated with an intravenous infusion of hydrochloric acid (HCl) or an HCl precursor such as ammonium chloride, which is metabolized to urea and HCl. (See
         <a class="local">
          'Treatment of metabolic alkalosis with acute or chronic kidney disease'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.552.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz WB, Van Ypersele de Strihou, Kassirer JP. Role of anions in metabolic alkalosis and potassium deficiency. N Engl J Med 1968; 279:630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           VAN GOIDSENHOVEN GM, GRAY OV, PRICE AV, SANDERSON PH. The effect of prolonged administration of large doses of sodium bicarbonate in man. Clin Sci 1954; 13:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roy A, Al-bataineh MM, Pastor-Soler NM. Collecting duct intercalated cell function and regulation. Clin J Am Soc Nephrol 2015; 10:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galla JH. Metabolic alkalosis. J Am Soc Nephrol 2000; 11:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barton CH, Vaziri ND, Ness RL, et al. Cimetidine in the management of metabolic alkalosis induced by nasogastric drainage. Arch Surg 1979; 114:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirsch BM, Sunder-Plassmann G, Schwarz C. Metabolic alkalosis in a hemodialysis patient--successful treatment with a proton pump inhibitor. Clin Nephrol 2006; 66:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luke RG, Galla JH. It is chloride depletion alkalosis, not contraction alkalosis. J Am Soc Nephrol 2012; 23:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galla JH, Gifford JD, Luke RG, Rome L. Adaptations to chloride-depletion alkalosis. Am J Physiol 1991; 261:R771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verlander JW, Madsen KM, Galla JH, et al. Response of intercalated cells to chloride depletion metabolic alkalosis. Am J Physiol 1992; 262:F309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner CA, Devuyst O, Bourgeois S, Mohebbi N. Regulated acid-base transport in the collecting duct. Pflugers Arch 2009; 458:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adamson R, Swenson ER. Acetazolamide Use in Severe Chronic Obstructive Pulmonary Disease. Pros and Cons. Ann Am Thorac Soc 2017; 14:1086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SCHWARTZ WB, HAYS RM, POLAK A, HAYNIE GD. Effects of chronic hypercapnia on electrolyte and acid-base equilibrium. II. Recovery, with special reference to the influence of chloride intake. J Clin Invest 1961; 40:1238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wall BM, Byrum GV, Galla JH, Luke RG. Importance of chloride for the correction of chronic metabolic alkalosis in the rat. Am J Physiol 1987; 253:F1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tannen RL, Bleich HL, Schwartz WB. The renal response to acid loads in metabolic alkalosis; an assessment of the mechanisms regulating acid excretion. J Clin Invest 1966; 45:562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           COOKE RE, SEGAR WE, CHEEK DB, et al. The extrarenal correction of alkalosis associated with potassium deficiency. J Clin Invest 1952; 31:798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eiam-Ong S, Kurtzman NA, Sabatini S. Regulation of collecting tubule adenosine triphosphatases by aldosterone and potassium. J Clin Invest 1993; 91:2385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Capasso G, Jaeger P, Giebisch G, et al. Renal bicarbonate reabsorption in the rat. II. Distal tubule load dependence and effect of hypokalemia. J Clin Invest 1987; 80:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bear R, Goldstein M, Phillipson E, et al. Effect of metabolic alkalosis on respiratory function in patients with chronic obstructive lung disease. Can Med Assoc J 1977; 117:900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller PD, Berns AS. Acute metabolic alkalosis perpetuating hypercarbia. A role for acetazolamide in chronic obstructive pulmonary disease. JAMA 1977; 238:2400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banga A, Khilnani GC. Post-hypercapnic alkalosis is associated with ventilator dependence and increased ICU stay. COPD 2009; 6:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faisy C, Meziani F, Planquette B, et al. Effect of Acetazolamide vs Placebo on Duration of Invasive Mechanical Ventilation Among Patients With Chronic Obstructive Pulmonary Disease: A Randomized Clinical Trial. JAMA 2016; 315:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taki K, Mizuno K, Takahashi N, Wakusawa R. Disturbance of CO2 elimination in the lungs by carbonic anhydrase inhibition. Jpn J Physiol 1986; 36:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brimioulle S, Berre J, Dufaye P, et al. Hydrochloric acid infusion for treatment of metabolic alkalosis associated with respiratory acidosis. Crit Care Med 1989; 17:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lisawat P, Gennari FJ. Approach to the hemodialysis patient with an abnormal serum bicarbonate concentration. Am J Kidney Dis 2014; 64:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huber L, Gennari FJ. Severe metabolic alkalosis in a hemodialysis patient. Am J Kidney Dis 2011; 58:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fall P, Szerlip HM. Continuous renal replacement therapy: cause and treatment of electrolyte complications. Semin Dial 2010; 23:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morabito S, Pistolesi V, Tritapepe L, et al. Continuous venovenous hemodiafiltration with a low citrate dose regional anticoagulation protocol and a phosphate-containing solution: effects on acid-base status and phosphate supplementation needs. BMC Nephrol 2013; 14:232.
          </a>
         </li>
         <li class="breakAll">
          Frick PG, Senning A. The treatment of severe metabolic alkalosis with intravenous N /10 or N /5 hydrochloric acid. Germ Med Monthly 1964; 9:242
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner CW, Nesbit RR Jr, Mansberger AR Jr. Treatment of metabolic alkalosis with intravenous hydrochloric acid. South Med J 1979; 72:1241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwun KB, Boucherit T, Wong J, et al. Treatment of metabolic alkalosis with intravenous infusion of concentrated hydrochloric acid. Am J Surg 1983; 146:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buchanan IB, Campbell BT, Peck MD, Cairns BA. Chest wall necrosis and death secondary to hydrochloric acid infusion for metabolic alkalosis. South Med J 2005; 98:822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knutsen OH. New method for administration of hydrochloric acid in metabolic alkalosis. Lancet 1983; 1:953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin WJ, Matzke GR. Treating severe metabolic alkalosis. Clin Pharm 1982; 1:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warren SE, Swerdlin AR, Steinberg SM. Treatment of alkalosis with ammonium chloride: a case report. Clin Pharmacol Ther 1979; 25:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bushinsky DA, Gennari FJ. Life-threatening hyperkalemia induced by arginine. Ann Intern Med 1978; 89:632.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2345 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.552.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4875677" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Role of anions in metabolic alkalosis and potassium deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13190687" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The effect of prolonged administration of large doses of sodium bicarbonate in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25632105" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Collecting duct intercalated cell function and regulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10665945" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Metabolic alkalosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31851" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Cimetidine in the management of metabolic alkalosis induced by nasogastric drainage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17140170" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Metabolic alkalosis in a hemodialysis patient--successful treatment with a proton pump inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22223876" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : It is chloride depletion alkalosis, not contraction alkalosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1928424" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Adaptations to chloride-depletion alkalosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1531735" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Response of intercalated cells to chloride depletion metabolic alkalosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19277700" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Regulated acid-base transport in the collecting duct.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28622013" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Acetazolamide Use in Severe Chronic Obstructive Pulmonary Disease. Pros and Cons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13749130" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Effects of chronic hypercapnia on electrolyte and acid-base equilibrium. II. Recovery, with special reference to the influence of chloride intake.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3688234" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Importance of chloride for the correction of chronic metabolic alkalosis in the rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5937027" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The renal response to acid loads in metabolic alkalosis; an assessment of the mechanisms regulating acid excretion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14955532" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The extrarenal correction of alkalosis associated with potassium deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8390478" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Regulation of collecting tubule adenosine triphosphatases by aldosterone and potassium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3112185" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Renal bicarbonate reabsorption in the rat. II. Distal tubule load dependence and effect of hypokalemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21028" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Effect of metabolic alkalosis on respiratory function in patients with chronic obstructive lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/578870" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Acute metabolic alkalosis perpetuating hypercarbia. A role for acetazolamide in chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19938966" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Post-hypercapnic alkalosis is associated with ventilator dependence and increased ICU stay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26836730" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Effect of Acetazolamide vs Placebo on Duration of Invasive Mechanical Ventilation Among Patients With Chronic Obstructive Pulmonary Disease: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3095576" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Disturbance of CO2 elimination in the lungs by carbonic anhydrase inhibition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2493354" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Hydrochloric acid infusion for treatment of metabolic alkalosis associated with respiratory acidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24731739" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Approach to the hemodialysis patient with an abnormal serum bicarbonate concentration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21621890" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Severe metabolic alkalosis in a hemodialysis patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21166876" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Continuous renal replacement therapy: cause and treatment of electrolyte complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24156306" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Continuous venovenous hemodiafiltration with a low citrate dose regional anticoagulation protocol and a phosphate-containing solution: effects on acid-base status and phosphate supplementation needs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24156306" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Continuous venovenous hemodiafiltration with a low citrate dose regional anticoagulation protocol and a phosphate-containing solution: effects on acid-base status and phosphate supplementation needs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/482977" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Treatment of metabolic alkalosis with intravenous hydrochloric acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6614322" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Treatment of metabolic alkalosis with intravenous infusion of concentrated hydrochloric acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16144181" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Chest wall necrosis and death secondary to hydrochloric acid infusion for metabolic alkalosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6132269" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : New method for administration of hydrochloric acid in metabolic alkalosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6764161" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Treating severe metabolic alkalosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/436363" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Treatment of alkalosis with ammonium chloride: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/717931" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Life-threatening hyperkalemia induced by arginine.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
